This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Tolerability of Xalatan in Patients (A6111128)

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: March 31, 2009
Last updated: February 18, 2011
Last verified: February 2011
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.

Condition Intervention Phase
Glaucoma Ocular Hypertension Drug: Xalatan 0.005% eye drops Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Observational Study Assessing The Efficacy And Tolerability Of Xalatan™ In Patients With Open Angle Glaucoma And /Or Ocular Hypertension.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Intraocular Pressure [ Time Frame: Screening, 10 days, 4 weeks and 12 weeks after beginning treatment ]
    Intraocular pressure was measured at each visit

  • Humphrey Perimetry Visual Field [ Time Frame: Visits 1 and 4 ]
    Analysis of visual field deficits for abnormalities.

Enrollment: 1289
Study Start Date: July 2005
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Study Drug - Xalatan 0.005% eye drops Drug: Xalatan 0.005% eye drops
ophthalmic solution dosed once daily for 3 months
Other Name: latanoprost

Detailed Description:
  • Efficacy data not collected or analyzed
  • Safety and tolerability of Xalatan assessed NA

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
adults with glauocma or ocular hypertension

Inclusion Criteria:

  • Patient with ocular hypertension at least 22mg Hg
  • Patient must be over 18 years old

Exclusion Criteria:

  • None listed in the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00950690

Pfizer Investigational Site
Alexandria, Egypt
Saudi Arabia
Pfizer Investigational Site
Jeddah, Saudi Arabia
United Arab Emirates
Pfizer Investigational Site
Umm Al Quwain, United Arab Emirates
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00950690     History of Changes
Other Study ID Numbers: A6111128
Study First Received: March 31, 2009
Results First Received: March 31, 2009
Last Updated: February 18, 2011

Keywords provided by Pfizer:
observational safety study

Additional relevant MeSH terms:
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Ophthalmic Solutions
Antihypertensive Agents
Pharmaceutical Solutions
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nasal Decongestants
Vasoconstrictor Agents
Respiratory System Agents processed this record on June 22, 2017